# Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.

> **NCT06039280** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 150 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** N Acetylcysteine
- **DRUG:** Dexamethasone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06039280
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-15
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039280, "Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06039280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*